Bispecific Nanoconjugates: Precision Therapy for Skin Cancer
Targeted Cancer Therapy using Bispecific Nanoconjugates
Tags: The University of Sydney, Australia, Healthcare & Lifesciences, Science & Exploration
This innovation introduces a bispecific nanoconjugate therapy combining metallic and magnetic nanoparticles to precisely target cancer cells and immune cells, enhancing their proximity for effective destruction. By using iron and silver-based nanoparticles as nanocarriers for bispecific antibodies, it improves targeting of EGRF-positive skin cancer cells while increasing serum stability and therapeutic efficacy. Applications include precision oncology, targeted immunotherapies, and minimally invasive cancer treatments. This technology reduces dosing frequency and enhances patient compliance by extending serum half-life and improving stability. Protected under international patent PCT/AU2023/050338, it represents a significant advancement in cancer immunotherapy.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Healthcare Provider; Nanotechnology
